Lu AA24493 (novel carbamoylated form of human erythropoietin (EPO)) is in clinical phase II in the treatment of Friedreich's ataxia and in clinical phase I in the treatment of acute ischaemic stroke. Ongoing studies in both programmes are expected to report data in the first half of 2011.
No comments:
Post a Comment